Teva sets $520 million aside to resolve FCPA matters with US
MLex Summary: Teva Pharmaceutical, an Israeli generic drug producer, has established a provision of about $520 million in anticipation of settling alleged Foreign Corrupt Practices Act violations with US authorities. Teva...To view the full article, register now.
Already a subscriber? Click here to view full article